ERYTECH Pharma (Euronext: ERYP – Nasdaq: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that it has entered into a strategic partnership with the German Red Cross Blood Donor Service Baden-Württemberg-Hessen (GRCBDS) to complement the existing alliance with the French Blood bank (EFS) for the supply of donor red blood cells to manufacture its product candidates, including eryaspase, in Europe.
The GRCBDS is one of the world’s largest blood and transfusion services, ensuring safe and adequate supply of blood products for approximately 30 million Germans (more than one-third of the German population). In addition to its focus on blood product supply and safety, GRCBDS provides laboratory and research support through its extensive network of health care professionals and has significant cell-based product manufacturing expertise. This partnership will allow ERYTECH to leverage GRCBDS as a key European supplier of donor red blood cells (RBCs) for the production of eryaspase and other ERYTECH product candidates at future manufacturing sites in Europe. This complements the Company’s existing alliance with the French Etablissement Francais du Sang (EFS), which will remain the primary source of supply of donor RBCs for ERYTECH’s product candidates manufactured in Lyon.
“This strategic partnership with the GRCBDS is consistent with our long-term strategy of selectively diversifying and expanding RBC sourcing for the production of our late stage candidate, eryaspase, and other product candidates,” stated Gil Beyen, Chief Executive Officer of ERYTECH. “Importantly, this supply agreement with the GRCBDS, along with our existing agreement with EFS, provides us with a second reliable partner with sufficient scale to enable the production of clinical and initial commercial supply of eryaspase in Europe. We look forward to a productive relationship with the GRCBDS.”
“We are pleased to enter into this agreement with ERYTECH as the development of RBC-based therapeutics is a highly innovative and exciting approach,” stated Erhard Seifried, Medical Director at the GRCBDS. “As leaders in the field of blood product procurement, we are happy to support ERYTECH as the company progresses its development plans with eryaspase and other therapeutic candidates.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace
